DV
Dividend Vision

BMEA — Biomea Fusion Inc

Biomea Fusion Inc (BMEA)

Total return is -92.9% over the past 5.3 years, 192.6 points behind SPY at 99.7%. Its deepest 1-year drawdown was 64.1%.

Biomea Fusion is a clinical-stage biopharmaceutical company developing oral medications for diabetes and obesity treatment, with lead programs including icovamenib candidates in Phase II trials for Type 1 and Type 2 diabetes, and BMF-650 in Phase I trials for obesity. The company does not currently distribute dividends. This security appeals to investors seeking exposure to early-stage drug development in the diabetes and obesity therapeutics space, though it carries the typical risks associated with clinical-stage biotechnology companies.

BMEA key facts

Asset type
Stock
Asset class
Equity
Inception date
04/16/2021
Last close
$1.32
Market cap
$92,543,280
Average volume
436011.0
Beta
-0.329
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.55